Helicobacter pylori (Hp) infection
Conditions
Interventions
Control group:Vonoprazan-Amoxicillin high-dose dual therapy
Vonoprazan, 20mg, bid, Amoxicillin, 1.0 per dose, tid, orally, for 14 days.
Treatment group:Treatment with Vonoprazan-Amoxicillin high-dose dual therapy combined with Saccharomyces boulardii
Vonoprazan 20 mg b.i.d. , Amoxicillin 1.0 g t.i.d. and Saccharomyces boulardii 500 mg
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 65 years, regardless of gender; 2. Patients with current Helicobacter pylori infection (positive result in any one of the following tests: histopathological examination, rapid urease test, C13/C14 urea breath test, stool Helicobacter pylori antigen test); 3. No previous history of Helicobacter pylori eradication therapy; 4. Subjects who agree to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients complicated with severe gastric diseases such as gastric ulcer and gastric cancer, or patients with central venous catheterization; 2. Use of antifungal agents, H2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs) and potassium-competitive acid blockers (P-CABs) within the past 2 weeks; use of bismuth agents, antibiotics (including traditional Chinese medicines with antibacterial effects) and probiotic preparations within the past 4 weeks; 3. Pregnant or lactating women; 4. Presence of other severe diseases that may interfere with the evaluation of this study, including severe hepatic, renal and cardiovascular diseases, malignant tumors and alcoholic intoxication; 5. Subjects with allergy to any study medication or a history of penicillin allergy; 6. Participation in other clinical trials within 3 months prior to enrollment; 7. Subjects unable to accurately describe their symptoms and personal willingness (e.g., psychosis, severe neurosis) and uncooperative with the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori (Hp) eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| incidence rate of adverse events;treatment adherence; | — |
Countries
China
Contacts
Public ContactWen Hongtao
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed